SecBot SecBot
144 ·Filed Nov 4, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed12d 10h ago SEC0001950047-26-010677
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is small and part of a pre-arranged 10b5-1 plan, so it does not signal a change in insider sentiment. Monitor for any acceleration of insider selling or changes to the 10b5-1 plan.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$8.81
T+0 close · Nov 4, 2026 · via day close
Latest settled
+11.01%
T+5 · $9.78 · next T+20 in 17d
Vs SPY
+7.72%
α at T+5
Latest observation
+4.44%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $8.81entry
  2. T+1 · 11d ago +8.06%α +7.75% · $9.52
  3. T+5 · 5d ago +11.01%α +7.72% · $9.78
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Daniel S. Lorrain, an officer of Contineum Therapeutics, filed a Form 144 notice of intent to sell 4,170 shares of common stock, valued at approximately $40,407 based on a recent market price of ~$9.69. The shares were acquired via restricted stock units in 2017. This is a relatively small sale relative to the company's $360M market cap and the insider's apparent holdings, and is part of a 10b5-1 plan with prior sales in September and October 2026.

Key Facts

  • Daniel S. Lorrain, an officer of Contineum Therapeutics, filed Form 144 on 2026-11-04.
  • Proposed sale of 4,170 shares of common stock, approximate value $40,407.
  • Shares acquired on 05/09/2017 via restricted stock units.
  • Sale is part of a 10b5-1 trading plan; prior sales occurred on 09/01/2026 (9,520 shares) and 10/01/2026 (4,170 shares).
  • Company market cap is $360M; the proposed sale represents ~0.01% of shares outstanding.

Financial Impact

Proposed sale of 4,170 shares worth ~$40,407, a small fraction of the officer's likely holdings and the company's market cap.

dilution

Risk Factors

  • Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market if it continues at an elevated pace.
  • No other insider transactions or company filings are provided for context; this is an isolated filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010677
Document: 0001950047-26-010677-index.html0001950047-26-010677
Document: 0001950047-26-010677.txt0001950047-26-010677

US Market Status

Market Closed · Opens in 6h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026